Lay Line Genomics S.P.A.
Records under this name other than patents Lay Line Genomics S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Lay Line Genomics S.P.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,715,666 | Method for the potentiation of opioid analgesics effects on pain Lapsed on the fee record Ended May 6, 2026 · USPTO record | Lapsed on the fee record | Ended May 6, 2026 | USPTO record |
| US 8,691,221 | Analgesic treatment with prolonged effect Lapsed on the fee record Ended Apr 8, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 8, 2026 | USPTO record |
| US 9,751,947 | Antibodies and derivatives thereof Lapsed on the fee record Ended Sep 5, 2025 · USPTO record | Lapsed on the fee record | Ended Sep 5, 2025 | USPTO record |
| US 7,988,966 | Method for the potentiation of opioid analgesics effects on pain Lapsed on the fee record Ended Aug 2, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 2, 2023 | USPTO record |
| US 8,257,710 | Method for the treatment of pain with humanized anti-nerve growth factor antibodies Formerly held Lapsed on the fee record Ended Sep 4, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 4, 2020 | USPTO record |
| US 8,246,956 | Humanized anti-nerve growth factor antibodies Formerly held Lapsed on the fee record Ended Aug 21, 2020 · USPTO record | Lapsed on the fee record | Ended Aug 21, 2020 | USPTO record |
| US 8,486,401 | Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF Term ended Term ended Jul 22, 2020 · USPTO record | Term ended | Term ended Jul 22, 2020 | USPTO record |
| US 7,601,352 | Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA Term ended Term ended May 26, 2020 · USPTO record | Term ended | Term ended May 26, 2020 | USPTO record |
| US 8,877,491 | Polynucleotides encoding humanized anti-NGF antibodies Formerly held Lapsed on the fee record Ended Nov 4, 2018 · USPTO record | Lapsed on the fee record | Ended Nov 4, 2018 | USPTO record |
| US 7,589,219 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method Lapsed on the fee record Ended Sep 15, 2013 · USPTO record | Lapsed on the fee record | Ended Sep 15, 2013 | USPTO record |